683 Capital Management LLC Cuts Holdings in Immunic, Inc. $IMUX

683 Capital Management LLC decreased its holdings in Immunic, Inc. (NASDAQ:IMUX) by 93.1% in the second quarter, Holdings Channel reports. The firm owned 62,458 shares of the company’s stock after selling 837,542 shares during the quarter. 683 Capital Management LLC’s holdings in Immunic were worth $44,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Aberdeen Group plc boosted its position in shares of Immunic by 678.1% during the second quarter. Aberdeen Group plc now owns 8,243,941 shares of the company’s stock valued at $5,750,000 after buying an additional 7,184,457 shares during the last quarter. Focus Partners Wealth lifted its stake in Immunic by 19.1% during the 1st quarter. Focus Partners Wealth now owns 2,583,457 shares of the company’s stock valued at $2,816,000 after acquiring an additional 415,104 shares during the period. Finally, Jane Street Group LLC boosted its holdings in shares of Immunic by 279.3% during the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock valued at $226,000 after acquiring an additional 152,726 shares during the last quarter. 51.82% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on IMUX. D. Boral Capital decreased their price objective on shares of Immunic from $10.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, November 13th. Roth Capital assumed coverage on shares of Immunic in a research note on Friday, November 7th. They set a “buy” rating and a $3.00 target price for the company. LADENBURG THALM/SH SH raised Immunic to a “strong-buy” rating in a report on Thursday, October 16th. Chardan Capital upgraded Immunic to a “strong-buy” rating in a research note on Wednesday, November 19th. Finally, HC Wainwright reduced their price objective on Immunic from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 14th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Immunic currently has a consensus rating of “Buy” and an average target price of $7.40.

Immunic Price Performance

NASDAQ:IMUX opened at $0.62 on Friday. The firm has a market capitalization of $74.76 million, a price-to-earnings ratio of -0.75 and a beta of 1.48. Immunic, Inc. has a one year low of $0.56 and a one year high of $1.39. The business has a fifty day moving average price of $0.76 and a 200-day moving average price of $0.82.

Immunic (NASDAQ:IMUX) last released its earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.05. On average, equities research analysts expect that Immunic, Inc. will post -0.94 earnings per share for the current fiscal year.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.